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Abstract 
Background: Cystinosis is a multisystemic autosomal recessive deficiency of 
the lysosomal membrane transporter protein (cystinosin) caused by muta-
tions in CTNS gene. Objective: This study summarizes the Portuguese expe-
rience in the diagnosis and management of patients with this rare disease 
over the past few years and reports recurrent mutations in the CTNS gene. 
Methods: Unrelated patients from different pediatric and adult hospitals all 
over Portugal with non-nephrotic proteinuria, hypercalciuria, hypokalemia 
impaired proximal reabsorption of amino acids, glycosuria and hypophos-
phatemia, suggestive of a Fanconi syndrome and ocular problems, were stu-
died. Intra-leukocyte cystine levels were determined and molecular analysis 
was performed, to determine the presence or absence of the 57-kb deletion in 
CTNS, followed by direct sequencing of the coding exons of CTNS. Results: 
From 1998 to 2017, twenty-one cystinotic patients were biochemically diag-
nosed. From the remaining seventeen (four deceased), eleven were studied 
for CTNS gene. Five out of eleven patients were homozygous for the 57-kb 
deletion (10/22; 45.5%), and other five were compound heterozygous for this 
variant (15/22; 68.2%). The other mutations found were p.Q128X (c.721 C>T; 
2/22), p.S139F (c.755 C>T; 4/22) and c.18-21delGACT (p.T7FfsX7; 1/22). All 
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of these seventeen cystinotic patients are in treatment. Approximately 84% 
are adults, 16% are young children, and 54.5% are kidney transplant reci-
pient. Conclusions: The authors would like to emphasize the importance of 
first screening for the 57-kb deletion since it is very common in our popula-
tion. This genetic study is the first in our country and it could be the basis for 
future genetic counseling in Portuguese population. 
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1. Introduction 
Cystinosis (OMIM #606272 ORPHA213) was first described in literature in 1903 
[1] and is a rare autosomal recessive systemic lysosomal storage disease charac-
terized by the abnormal accumulation of lysosomal cystine due to mutations in 
the cystinosin gene (CTNS) [2]. The CTNS gene is localized on human chromo-
some 17p13 contains 12 exons, the first two of which are non-coding [2] [3] and 
the other ten encode a 367 amino acid protein named cystinosin. The incidence 
of this disease is estimated to be 1 in 100,000 - 200,000 live births, though exact 
numbers are difficult to obtain because the disease is often undiagnosed and/or 
misdiagnosed. Cystinosis is the most frequent cause of inherited Fanconi syn-
drome and should be considered the initial differential diagnosis. Nevertheless, 
the severity of Fanconi Syndrome associated with cystinosis requires rigorous 
treatment that is frequently complex [4]. Although the kidneys are initially af-
fected during the first year of life, in most of the cases, other potentially affected 
organs include also eyes, thyroid, pancreas, gonads, muscles and CNS over time 
[3] [5]. The severity of the phenotype is correlated with the genotype. Accurate 
measurement of intracellular cystine content is obligatory for the diagnosis of 
cystinosis and still the cornerstone for both diagnosis and therapeutic monitor-
ing of the disease [6].  
The most commonly detected cystinosis mutation is a 57-kb deletion that de-
letes the majority of CTNS gene [7] [8] and in general, is related with high doses 
of cystine in leukocytes. This deletion is present in almost 50% of all the North-
ern European and North American origin [3] [7]-[13]. However, outside this 
geographical distribution, the mutation is almost completely absent, especially in 
the Middle East [14] [15] [16], therefore migration and/or ethnicity could be the 
explanation for this fact as well as the concept of possible other founder muta-
tion from those regions [3]. Since the cloning of CTNS gene, over 200 patho-
genic mutations have been reported in different ethnic groups, including muta-
tions in the promoter region, missense, nonsense, deletion, insertion and splice 
mutations(http://www.hgmd.org/) [13] [17]. 
Cystinosis has three major clinical presentations: the most serious form, the 
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infantile nephropathic form or classical nephropathic cystinosis (MIM 219800), 
a less severe form, the juvenile nephropathic form (MIM 219900) and the ocular 
non-nephropathic form (MIM 219750) [18]. The infantile or classical cystinosis, 
comprising about 95% of all cases. The non-nephropathic, or ocular cystinosis 
manifests exclusively with ocular involvement due to cystine crystals deposition 
[18] [19] [20]. In some patients, ocular involvement can precede renal manife-
station by several years [21]. It has been hypothesized that the underlying dif-
ferences between the clinical forms and the severity of them is because individu-
als with infantile cystinosis harbour “severe” mutations (i.e. loss of function) on 
both alleles, whereas individuals with milder forms of cystinosis harbour a spe-
cific, non-severe mutation (i.e. never observed in cases of infantile cystinosis) 
either on both alleles or in association with a severe allele (compound hetero-
zygous) that is why is so important to characterized the mutation spectrum of 
this disease [7] [22] [23] [24]. Molecular analysis of the CTNS gene also con-
firms the diagnosis and offers the advantage of a prenatal diagnosis [25]. Several 
lines of treatment are available for cystinosis. When started at an early age, cys-
teamine treatment prevents or postpones the deterioration of renal function and 
the occurrence of extra-renal complications such as hypothyroidism, diabetes 
mellitus, retinopathy, encephalopathy and myopathy [26] [27].  
The aim of this study was to determine the mutational spectrum of Portu-
guese population for cystinosis, as well as established a genotype/phenotype 
correlation to the mutation found with the respective cystine intra-leucocytes 
value and the clinical presentation. This study is the first one in the Portuguese 
population. 
2. Material and Methods 
2.1. Patients 
Studies were conducted from 1998 to 2017, where a total of 1,941,372 newborns 
were registered. In this cohort, 32 unrelated patients from different pediatric and 
adult hospitals all over Portugal had non-nephrotic proteinuria (<3.5 g pro-
tein/24H), hypercalciuria, hypokalemia, impaired proximal reabsorption of 
amino acids (hyperaminoaciduria), glycosuria and hypophosphatemia, sugges-
tive of a Fanconi syndrome. Later, all developed also ocular complains, that re-
vealed intraocular cystine crystals, a very important find to correlate this Fanco-
ni syndrome with cystinosis. Although most patients had Fanconi syndrome 
(20/21), one patient had no Fanconi syndrome but an earlier nephrotic chronic 
disease (with kidney damage and >3.5 g protein/24H) diagnosed only in adoles-
cence (at the age of 15 years). In this particular patient, the diagnosis of the ju-
venile nephropatic form of cystinosis was done when she got pregnant. In fact, 
from these 32 patients, 21 patients revealed high values of intra-leukocytes cys-
tine in blood (≥0.50 nmol 1/2 cystine/mg protein). Unfortunately, from these 21 
patients (8 males, and 13 females, with ages between 1 - 40 years), four deceased, 
two we lost the clinical history (i.e. emigration) and from the remaining fifteen, 
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only eleven were characterized at a molecular level. From this study, it seems 
that generally, not only ocular cystine crystals preceded Fanconi syndrome, but 
also contributes to the correct final diagnosis. The authors would like to em-
phasize, that from these 21 positive cystinosis patient, only one patient was di-
agnosed in adulthood (at the age of 40 years old) due to presence of intraocular 
cystine crystals, although he have had chronic nephrotic complains (such as 
proteinuria, calciuria, hypokalemia and hyperaminoaciduria) since pediatric age. 
2.2. Ethics Statement 
All procedures were followed in accordance with the ethical standards of the re-
sponsible committee on human experimentation (institutional and national) and 
with the Helsinki Declaration of 1975, as revised in 2000 and approved by the 
Ethics Committees. Informed consent was obtained from all patients and their 
families for being included in the study.  
2.3. Biochemical Methods 
The specific biochemical diagnosis was performed by study of urine and the de-
tection of elevated intra-leukocyte cystine levels (Whole Blood Cells Cystine in-
tra-leukocyte levels; WBC Cis IL) [28]. Prior extraction, cystine quantification 
was obtained by ion exchange liquid chromatography in a BIOCHROM 30®. The 
reference values used were: 
 Healthy individual: <0.5 nmol 1/2 cystine/mg protein.  
 Affected individuals without treatment: ≥0.5 nmol 1/2 cystine/mg protein. 
 Individuals treated with good therapeutic control: ≤1.0 nmol 1/2 cystine/mg 
protein. 
2.4. Molecular Diagnosis 
Genomic DNA was automatically extracted from whole blood or dried blood 
spots, using an automated method (EZ1 DNA Blood 350 μl, or EZ1 DNA tissue 
kit, QIAGEN). The ten protein-coding exons and flanking intronic sequences of 
CTNS gene (NM_004937) were directly sequenced after PCR amplification in an 
ABI PRISMTM 3130XL Genetic Analyzer (Applied Biosystems, Foster City, CA, 
USA) [7]. All patients were first screened for the 57-kb and if negative, whole 
CTNS gene was sequenced. As a control population, we studied 100 healthy (200 
alleles) unrelated individuals of Portuguese origin.  
3. Results and Discussion 
During 19 years, 32 patients with non-nephrotic proteinuria, hypercalciuria, 
hypokalemia, hyperaminoaciduria, glycosuria and hypophosphatemia, sugges-
tive of a renal Fanconi syndrome and/or ophthalmologic symptoms were bio-
chemically evaluated due to cystinosis clinical suspicion. Usually the diagnosis is 
made shortly after the onset of the symptoms but some delay may occur due to 
the low specificity of the symptoms. From those 32 patients suspected, 11 had an 
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intra-leukocytes cystine value below 0.5 nmol 1/2 cystine/mg protein in two 
successive samples [4] and they were considered negative for cystinosis and oth-
er causes were investigated. In the remaining 21, intra-leukocytes cystine rang-
ing from 0.5 to 8.0 nmol 1/2 cystine/mg protein was confirmed and eleven of 
these were studied for CTNS gene mutations, four pathogenic reported CTNS 
mutations were detected, being the common European 57-kb deletion the most 
frequent (68.2%; 15/22 alleles). Five out of eleven patients were homozygous for 
the 57-kb deletion, and five were compound heterozygous for 57-kb deletion 
(45.5%) and p.Q128X (c.721 C>T; 9.1%), p.S139F (c.755 C>T; 9.1%) and 
c.18-21delGACT (p.T7FfsX7; 4.5%), mutations (Table 1). One patient was ho-
mozygous for p.S139F mutation. From the literature, it seems that this mutation 
in homozygous state is the first time found. We can also conclude that patients 
with severe or truncating mutations, as the 57-kb deletion and p.T7FfsX7 or 
p.Q128X had the infantile severe form of the disease, while juvenile cystinosis 
was associated with at least one mild mutation. We found that patients with the 
57-kb deletion had higher cystine intra-leukocyte levels (WBC Cis IL), which is 
also in concordance with the literature (Table 1), because this specific mutation 
results in the absence of protein [4] [8]. In Portugal, it is estimated that this dis-
ease has an incidence of 1/92,000 newborns. 
The most common CTNS mutation in Northern Europe is the 57-kb deletion, 
which is in accordance with our results. In fact, the 57-kb deletion accounts for 
about 50% of cystinosis chromosomes in European populations [29] [30]. It is 
thought that this deletion has arisen because of a founder effect, originated in 
Germany around the middle of the first millennium A.D. [3] [7] [9]. The hypo-
thesis of this deletion having arisen in the Northern Europe and having spread 
throughout Europe toward Northern Africa by migration is consistent with a 
north to south gradient as already found for the p.F508del cystic fibrosis muta-
tion. In fact, African influence is largely concentrated in the Southern and 
Western regions of Europe, and Germanic influence is small and limited. 
Therefore, when comparing our results with other countries from North Euro-
pean and North American origin, the 57-kb deletion in Portugal is also the most 
prevalent mutation (68.2% of the mutant alleles). This is also true, for other 
countries, as Spain [12], which has a 57-kb deletion prevalence of 34%, in Neth-
erlands [31] 59% and 65% in Switzerland-Germany population [11], but it de-
creases to 17% in Italy [14] and is absent in Turkish population. At a first glance, 
we should expect to have a cystinosis spectrum mutation similar to the Southern 
Europe population (i.e. due to our emigration history), but in fact does not hap-
pen. We have a different mutational spectrum for CTNS gene comparing with 
the mutational spectrum of African, Mediterranean and Middle East popula-
tions. Indeed, it seems that outside this geographical distribution (North Europe 
and North America), the 57-kb deletion is almost absent, especially in the Mid-
dle East [32] which appears instead to have a common exonic splice site muta-
tion; p.E227E (c.681 G>A) [33]. In fact, this mutation, comprises 39.5% of the 
Iranian [15], 20% of Turkish [34] and 15.4% of Saudi familial mutant alleles [33]  
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Table 1. Correlation between the genotype, value of intra-leukocyte cystine at the age of 
diagnosis and presentation form of cystinosis in the studied patients. 
Mutation Status Patients 
Intra-Leukocyte Cystine Value 
at Diagnosis 
(nmol1/2cystine/mg protein) 
Presentation  
Form of Cystinosis 
57-kb deletion/57-kb deletion (N = 5) [2.8 - 8.0] 
Infantile  
Nephropathic form 
57-kb deletion/Q128X (N = 2) [1.5 and 5.1] 
Infantile  
Nephropathic form 
57-kb deletion/p.T7FfsX7 (N = 1) [7.3] 
Infantile  
Nephropathic form 
p.S139F/p.S139F (N = 1) [1.7] 
Juvenile (late) 
Nephropathic form 
57-kb deletion/S139F (N = 2) [2.2 and 3.7] 
Juvenile  
Nephropathic form 
 
and was not detected previously in European or American populations. So, it 
seems that toward to Mediterranean region, the frequency of the 57-kb deletion 
decreases. Nevertheless, the 57-kb deletion should be the first mutation for 
looking for in cystinosis patients from Portugal or as well as from Spain [4]. The 
other mutations; p.S139F as well as the c.18-21delGACT (p.T7FfsX7), have a 
Spanish founder gene [12], but an interesting fact is that, the deletion 
c.18-21delGACT (p.T7FfsX7) has been found in different populations from Eu-
rope to Middle East, and with widely disease severities. From the cohort studied, 
we do not have none ocular non-nephropathic form of cystinosis (Table 1), that 
could be related to the rarity of that form of the disease. 
We suggest that this fact is due to the difficulty of established this diagnosis 
and most ophthalmologists do not suspect of this disease. The prognosis of cys-
tinosis depends on early diagnosis and or the prompt start and good compliance 
with cysteamine treatment. From our point of view, it is important to reinforce 
the need to diagnosis cystinosis as earlier as possible, and begin therapy with 
cystine-depleting agents as soon as the diagnosis is made. In this way, it may be 
possible to attenuate the renal tubular Fanconi syndrome and significantly slow 
the progression of glomerular damage. Kidney disease progression, extra-renal 
complications and shorter life expectancy are more evident in patients who do 
not adhere to treatment.  
4. Conclusions 
Four different mutations were identified: one large deletion (57-kb deletion), 
one small deletion (c.18-21delGACT) that originated a frameshift mutation 
(p.T7FfsX7), one missense mutation (p.S139F) and one nonsense mutation that 
originates a premature stop codon (p.Q128X). The 57-kb deletion is the most 
common mutation found in the Portuguese patients (68.2%).  
The authors would like to emphasize the importance of first screening for the 
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57-kb deletion since it is very common in our population, although the deter-
mination of intra-leukocytes cystine (WBC Cis IL) is also an important tool for 
the cystinosis diagnosis and therapeutic monitorization. Although, it is impor-
tant to notice that in small infants, WBC Cis IL may result in a false negative. 
This genetic study is the first in our country and it could be the basis for future 
genetic counseling and prenatal diagnosis of patients with nephropathic cystino-
sis in Portuguese population. Prenatal diagnosis allows for early cysteamine 
treatment. We also like to emphasize that, to those countries with high rate of 
consanguinity, the incidence of cystinosis is predicted to be higher, we should 
suggest in a potential universal neonatal screening for cystinosis. 
Take Home Message 
Mutational spectrum of Portuguese population for cystinosis. This study is the 
first one in the Portuguese population. 
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